{"title":"[Anxiety and Generalized Anxiety Disorder in Elite Athletes].","authors":"Laura Pires, Sofia Gomes, Paula Freitas","doi":"10.20344/amp.21600","DOIUrl":"https://doi.org/10.20344/amp.21600","url":null,"abstract":"<p><p>Physical activity is recommended as a strategy for promoting mental health, and it can even be integrated into treatment plans for psychiatric disorders affecting the general population. However, elite athletes are a subpopulation with protective and risk factors inherent to high-level competition and are not shielded from psychiatric symptoms and conditions. The mental health of elite athletes has been the subject of increasing attention, driven in part by the initiatives of the International Olympic Committee and the growing importance of sports psychiatry. This article is a narrative review that provides an overview regarding anxiety, in particular generalized anxiety disorder in elite athletes. Our assessment concluded that competitive anxiety may affect an elite athlete's performance in both harmful and beneficial ways. Assessing the duration, frequency, and functional impact of anxiety symptoms is crucial for ruling out generalized anxiety disorder. Elite athletes do not show a significantly different prevalence of generalized anxiety disorder compared to the general population. Identifying specific protective and risk factors can contribute to adopting more effective preventive and intervention strategies. As in the general population, psychotherapy is recommended for elite athletes as the initial treatment for this condition, combined, if necessary, with pharmacotherapy, according to the World Anti-Doping Agency Code.</p>","PeriodicalId":7059,"journal":{"name":"Acta medica portuguesa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniela A Rodrigues, Fátima Roque, Maria Teresa Herdeiro, Luís Monteiro
{"title":"Translation and Adaptation of the STOPP/START Criteria Version 3 for Potentially Inappropriate Prescribing in Older People to European Portuguese: A Study Protocol.","authors":"Daniela A Rodrigues, Fátima Roque, Maria Teresa Herdeiro, Luís Monteiro","doi":"10.20344/amp.21941","DOIUrl":"https://doi.org/10.20344/amp.21941","url":null,"abstract":"<p><strong>Introduction: </strong>As the global population ages, managing medication use in older adults becomes increasingly complex due to polypharmacy and the associated risks of adverse drug events. To improve the safety and appropriateness of medication use in the older population, tools like the Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert doctors to Right Treatment (START) criteria have been developed. The availability of updated criteria is crucial to better support healthcare professionals in Portuguese-speaking regions. The aim of this study is to translate and validate the STOPP/START version 3 criteria for Portuguese, providing an updated and useful tool for healthcare professionals.</p><p><strong>Methods and analysis: </strong>This study will be conducted through four phases: I) translation of the STOPP/START version 3 criteria to European Portuguese; II) collection of sociodemographic, clinical, and medication data; III) intrarater reliability study; and IV) interrater agreement study. This study obtained ethics approval by the Ethics Committee of the Administração Regional de Saúde do Centro, Portugal. The availability of the translated criteria will enable the integration of STOPP/START version 3 into clinical practice in Portugal, facilitating improved medication safety and appropriateness. This integration is expected to lead to better management of polypharmacy and a reduction in adverse drug events, ultimately enhancing patient outcomes and supporting evidence-based prescribing practices.</p>","PeriodicalId":7059,"journal":{"name":"Acta medica portuguesa","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}